|
Case
|
Anti-viral
|
Immunosuppressive therapy
|
Follow-up time (months)
|
Scr (μmol/L)
|
eGFR (ml/min per 1.73m2)
|
24hUP (g/d)
|
Cryocrit(%)
|
HBV-DNA (copies/ml)
|
Outcome
|
|---|
|
1
|
ETV
|
CS + MMF
|
37
|
90
|
67.00
|
0.80
|
NA
|
< 103
|
PR
|
|
2
|
ETV
|
CS + CYC + DFPP
|
22
|
99
|
55.30
|
2.05
|
7.0
|
< 103
|
PR
|
|
3
|
ETV
|
CS + CYC + DFPP
|
6
|
60
|
111.80
|
0.05
|
0
|
< 103
|
CR
|
|
4
|
LAM
|
CS + CYC
|
3
|
119
|
54.13
|
3.77
|
NA
|
NA
|
death
|
|
5
|
ETV
|
CS
|
62
|
80
|
114.00
|
0.90
|
2.0
|
1.24 × 104
|
PR
|
|
6
|
ETV
|
CS
|
12
|
287
|
20.70
|
5.22
|
NA
|
NA
|
death
|
|
7
|
ETV
|
CS + CYC
|
18
|
900
|
5.50
|
9.92
|
0
|
< 103
|
dialysis
|
- Scr Serum creatinine, eGFR Estimated glomerular filtration rate, 24hUP 24-h urine protein, ETV Entecavir, LAM Lamivudine, CS Corticosteroid, MMF Mycophenolate, CYC Cyclophosphamide, DFPP Double-filtration plasmapheresis, CR Complete remission, PR Partial remission, NA Not available
